Pfenex (NYSEAMERICAN:PFNX)‘s stock had its “outperform” rating reiterated by research analysts at William Blair in a research note issued on Friday, March 16th. William Blair also issued estimates for Pfenex’s Q1 2019 earnings at ($0.33) EPS, Q2 2019 earnings at ($0.35) EPS, Q3 2019 earnings at ($0.44) EPS and Q4 2019 earnings at ($0.41) EPS.
Separately, Zacks Investment Research downgraded Pfenex from a “hold” rating to a “sell” rating in a research note on Friday, January 5th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $7.67.
Shares of PFNX traded down $0.16 during trading on Friday, reaching $5.40. The company’s stock had a trading volume of 69,983 shares, compared to its average volume of 132,165. Pfenex has a twelve month low of $2.07 and a twelve month high of $6.77.
Pfenex (NYSEAMERICAN:PFNX) last issued its quarterly earnings results on Thursday, March 15th. The biotechnology company reported $0.23 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.22 by $0.01. Pfenex had a negative return on equity of 63.57% and a negative net margin of 175.52%. The business had revenue of $17.91 million during the quarter, compared to the consensus estimate of $5.00 million.
Several institutional investors have recently made changes to their positions in the company. Dimensional Fund Advisors LP lifted its holdings in shares of Pfenex by 112.1% during the second quarter. Dimensional Fund Advisors LP now owns 201,066 shares of the biotechnology company’s stock valued at $806,000 after purchasing an additional 106,257 shares during the last quarter. Spark Investment Management LLC raised its position in Pfenex by 126.6% during the fourth quarter. Spark Investment Management LLC now owns 69,100 shares of the biotechnology company’s stock valued at $183,000 after buying an additional 38,600 shares during the period. Mackenzie Financial Corp acquired a new position in Pfenex during the fourth quarter valued at $588,000. Renaissance Technologies LLC raised its position in Pfenex by 26.3% during the fourth quarter. Renaissance Technologies LLC now owns 1,010,600 shares of the biotechnology company’s stock valued at $2,688,000 after buying an additional 210,600 shares during the period. Finally, Franklin Resources Inc. raised its position in Pfenex by 1.1% during the fourth quarter. Franklin Resources Inc. now owns 2,783,060 shares of the biotechnology company’s stock valued at $7,403,000 after buying an additional 31,295 shares during the period.
TRADEMARK VIOLATION NOTICE: This story was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. & international trademark and copyright laws. The original version of this story can be viewed at https://www.dispatchtribunal.com/2018/04/08/pfenex-pfnx-given-outperform-rating-at-william-blair.html.
Pfenex Company Profile
Pfenex Inc, a clinical-stage biotechnology company, develops biosimilar therapeutics in the United States. Its lead product candidates include PF708, a therapeutic equivalent candidate to Forteo (teriparatide) for the treatment of osteoporosis; PF582, a biosimilar to Lucentis (ranibizumab) for the treatment of patients with retinal diseases; and Px563L, a novel anthrax vaccine candidate in Phase 1a trial.
Receive News & Ratings for Pfenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfenex and related companies with MarketBeat.com's FREE daily email newsletter.